# TUMOR SUPPRESSOR GENES IN CARCINOGENESIS
## MD Pathology Examination Answer (10 Marks)
### Emphasis on p53 and Rb

---

## INTRODUCTION (1 mark)

Tumor suppressor genes are a class of cancer genes that encode protein products that apply "brakes" to cell proliferation. Unlike oncogenes (which promote growth when activated), tumor suppressors normally prevent uncontrolled cell growth through multiple mechanisms including cell cycle arrest, apoptosis, and DNA repair. Loss-of-function mutations in these genes contribute to malignant transformation. Over 80% of human cancers carry loss-of-function mutations in tumor suppressor genes, making them crucial targets in carcinogenesis.

---

## GENERAL CHARACTERISTICS OF TUMOR SUPPRESSOR GENES (2 marks)

### 1. **Two-Hit Hypothesis (Knudson's Model)**
- Both alleles of a tumor suppressor gene must be inactivated for complete loss of function
- In familial cancer syndromes: one defective allele is inherited (germline mutation), and the second allele is lost in somatic cells
- In sporadic cancers: both mutations are acquired during a cell's lifetime
- This differs from oncogenes, where a single mutation can cause constitutive activation

### 2. **Mechanisms of Inactivation**
- **Homozygous deletion**: Complete loss of both gene copies
- **Point mutations**: Scattered throughout the open reading frame (unlike oncogene "hotspots")
- **Large deletions**: Loss of functional product, sometimes entire chromosome arms
- **Epigenetic silencing**: Promoter methylation, histone modifications without DNA sequence change

### 3. **Functional Categories**
- Cell cycle regulators (RB, p16)
- DNA damage response proteins (p53, ATM, BRCA1/BRCA2)
- DNA repair genes (mismatch repair genes, nucleotide excision repair genes)
- Apoptosis regulators
- Growth inhibition mediators

---

## RB (RETINOBLASTOMA PROTEIN): GOVERNOR OF THE CELL CYCLE (3.5 marks)

### A. **Discovery & Clinical Significance**
- First tumor suppressor gene identified, discovered through study of retinoblastoma (childhood eye cancer)
- Approximately 60% of retinoblastomas are sporadic; 40% familial with autosomal dominant inheritance
- Loss-of-function RB mutations also found in osteosarcoma, glioblastoma, lung, breast, and bladder carcinomas
- RB is expressed in all cells, yet germline RB mutations preferentially cause retinoblastoma (possibly due to functional substitution by related proteins in other cell types)

### B. **Molecular Function: RB and Cell Cycle Control**

**RB as a G1/S Checkpoint Regulator:**
- RB acts as a key negative regulator of the G1/S checkpoint—the most critical restriction point in the cell cycle
- In quiescent (G0) cells and early G1: RB is hypophosphorylated and actively binds E2F transcription factors, sequestering them and preventing transcription of S-phase genes
- During G1 progression: Growth factor signals activate CDK4/6-cyclin D complexes, which hyperphosphorylate RB
- Phosphorylation inactivates RB, releasing E2F transcription factors
- Liberated E2F drives expression of:
  - Histone genes
  - DNA replication proteins
  - CDK2-cyclin E complexes
  - This allows progression from G1 to S phase

**RB as Signal Integration Point:**
- Growth-promoting signals → increase CDK/cyclin complexes → phosphorylate and inactivate RB
- Growth-inhibitory signals → upregulate CDK inhibitors (p16, p21) → maintain RB hypophosphorylated
- RB integrates these opposing signals, making it a central checkpoint controller

### C. **Mechanisms of Functional Loss in Cancer**
The paradigm: **loss of normal cell cycle control is central to malignant transformation**, with dysregulation of at least one of four key regulators:
- Direct RB gene loss-of-function mutations
- Overexpression/amplification of cyclin D (common in breast, esophageal, hepatic cancers)
- Overexpression/amplification of CDK4 (common in melanomas, sarcomas, glioblastomas)
- Loss/inactivation of CDK inhibitors (p16/CDKN2A mutations in familial melanomas)

**Viral Oncoproteins Targeting RB:**
- Large T antigen (polyomaviruses) and HPV E7 protein bind the same "pocket" domain that RB uses to bind E2F
- Viral proteins inactivate RB → E2F release → uncontrolled S-phase entry
- This demonstrates the biological importance of RB in controlling growth

### D. **Cellular Consequences of RB Inactivation**
- Loss of G1/S checkpoint control
- Uncontrolled S-phase entry despite growth inhibitory signals
- Excessive cell proliferation
- Increased genomic instability (cells divide without DNA damage checkpoints)
- Prerequisite for malignant transformation

---

## p53 (TP53): GUARDIAN OF THE GENOME (3.5 marks)

### A. **Prevalence & Significance**
- **Most frequently mutated gene in human cancers**: >50-80% of human tumors carry p53 loss-of-function mutations
- Particularly common in:
  - Smoking-induced squamous cell carcinomas of the head and neck (84% TP53 mutation rate)
  - Colorectal cancers
  - Breast cancers
  - Lung cancers
  - Ovarian cancers
- Germline TP53 mutations cause Li-Fraumeni syndrome (familial cancer syndrome with high risk of multiple malignancies)

### B. **Molecular Function: p53 as Transcription Factor**

**DNA Damage Response & Activation:**
- p53 is a transcription factor that responds to cellular stresses
- Normally has short half-life (~20 minutes) due to binding by MDM2, which targets it for proteasomal degradation
- Upon DNA damage detection:
  - Sensor kinases (ATM, ATR) are activated
  - These phosphorylate p53
  - Phosphorylation releases p53 from MDM2 binding
  - p53 half-life increases dramatically (stabilization)
  - p53 accumulates in the nucleus

**Three Main Functions of p53:**

#### 1. **Cell Cycle Arrest (G1/S Checkpoint)**
- p53 upregulates transcription of p21 (CDK inhibitor/CDKI)
- p21 inhibits cyclin-CDK complexes (CDK2-cyclin E, CDK4/6-cyclin D)
- Cyclin-CDK inhibition prevents RB phosphorylation
- RB remains active, sequestering E2F → blocks S-phase entry
- Provides time for DNA repair mechanisms to act
- If DNA is successfully repaired → p53 levels drop → cell cycle resumes
- This is the primary brake on cell proliferation in response to DNA damage

#### 2. **DNA Repair**
- p53 induces expression of DNA repair genes (GADD45, XPC, DDB2)
- Facilitates nucleotide excision repair, base excision repair, and mismatch repair
- Allows damaged DNA to be fixed before replication
- Critical for maintaining genomic integrity

#### 3. **Apoptosis (Programmed Cell Death)**
- If DNA damage cannot be repaired, p53 triggers apoptosis
- Upregulates pro-apoptotic genes (BAX, PUMA, NOXA)
- Downregulates anti-apoptotic gene BCL2
- Damaged cell undergoes programmed death rather than risking malignant transformation
- Irreversibly eliminates cells with unrepaired mutations

**Alternative Function: Senescence**
- p53 can also direct cells into permanent growth arrest (cellular senescence)
- Prevents unlimited replicative potential
- Acts as a backup mechanism to apoptosis

### C. **p53 in Normal vs. Stressed Cells**

| Condition | p53 Status | Cellular Outcome |
|-----------|-----------|-----------------|
| Normal, unstressed | Low (short half-life) | Limited growth inhibition; normal cell cycle |
| DNA damage (mild) | Elevated, stabilized | G1 arrest + DNA repair |
| DNA damage (severe) | Elevated, stabilized | Apoptosis or senescence |
| p53 mutation/loss | Absent or non-functional | No checkpoint control; mutations accumulate |

### D. **Consequences of p53 Loss in Cancer**

**Loss of "Guardian" Function:**
- Cells tolerate and accumulate DNA damage without triggering apoptosis
- Bypass of G1/S checkpoint even with damaged DNA
- Resistance to therapeutic DNA-damaging agents (chemotherapy, radiation)
- Rapid progression from precancerous to advanced malignancy
- High genomic instability and mutation burden
- Poor prognosis in many cancer types

**Regulation by MDM2:**
- Negative feedback loop: p53 induces MDM2 transcription → MDM2 targets p53 for degradation
- Oncogenic mutations can disrupt this feedback (e.g., MDM2 amplification)
- HPV E6 protein and SV40 T antigen also bind and inactivate p53 via proteasomal degradation

---

## COMPARATIVE SUMMARY: p53 vs. RB (1 mark)

| Feature | p53 | RB |
|---------|-----|-----|
| **Primary Function** | DNA damage response & apoptosis | Cell cycle checkpoint control (G1/S) |
| **Activation Trigger** | DNA damage, cellular stress | Growth factor signals, CDK activity |
| **Mechanism** | Transcription factor (activates target genes) | Protein-protein interaction (binds E2F) |
| **Key Targets** | p21, BAX, GADD45, PUMA | E2F transcription factors |
| **Cancer Prevalence** | >50-80% of cancers | ~20-30% of cancers (varies by type) |
| **Loss Effect** | Genomic instability; loss of apoptosis | Uncontrolled S-phase entry; loss of checkpoint |
| **Clinical Syndrome** | Li-Fraumeni (germline TP53) | Familial retinoblastoma |

---

## MULTISTEP CARCINOGENESIS: INTEGRATION OF TUMOR SUPPRESSORS (1 mark)

**The Modern Model:**
- Malignant tumors arise from sequential accumulation of cancer-promoting alterations
- Both **oncogenes** (gain-of-function) and **tumor suppressors** (loss-of-function) must be dysregulated
- p53 and RB mutations often co-occur in advanced cancers
- Example: Colorectal cancer progression
  - Early loss: APC (tumor suppressor)
  - Intermediate: KRAS activation (oncogene)
  - Late: TP53 loss (tumor suppressor)
  - Result: Progression from normal → adenoma → dysplasia → carcinoma

- Genome-wide sequencing reveals that most cancers harbor mutations in both:
  - Multiple oncogenes
  - Multiple tumor suppressor genes
- This explains why cancer is typically a disease of accumulated mutations over time

---

## CLINICAL RELEVANCE & THERAPEUTIC IMPLICATIONS (1 mark)

### Diagnostic Use:
- p53 immunohistochemistry (IHC) useful in tumor classification and prognosis
- p53-mutant tumors often show poor response to therapy
- Testing for p53 mutations in hereditary cancer syndromes

### Therapeutic Opportunities:
- **CDK4/6 inhibitors**: Restore RB checkpoint by blocking cyclin D-CDK4/6 complexes
  - Used in breast cancer (especially RB-positive, hormone receptor-positive tumors)
  - Indirectly protects RB function by preventing its phosphorylation
  
- **p53 restoration therapies**: Under development
  - Reactivating mutant p53 (e.g., APR-246)
  - MDM2 inhibitors (prevent p53 degradation, allowing accumulation)
  - Nutlin class of MDM2 inhibitors
  
- **Checkpoint inhibitors**: Immunotherapy targeting DNA damage responses
  - Particularly in p53-mutant tumors

### Prognosis:
- p53 mutations often indicate aggressive behavior and poor prognosis
- Loss of RB correlates with certain tumor types and treatment resistance

---

## KEY EXAMINATION POINTS TO REMEMBER

1. **Tumor suppressors** = "brakes on cell growth"; need both alleles inactivated (two-hit hypothesis)
2. **RB** = controls G1/S checkpoint via E2F sequestration; most critical for preventing S-phase entry
3. **p53** = responds to DNA damage; triggers arrest, repair, or apoptosis; "guardian of genome"
4. Over 80% of cancers have p53 mutations; RB mutations less frequent but still significant
5. RB and p53 losses often co-occur in advanced cancers
6. Loss of tumor suppressors requires multiple hits; oncogenes require single hit (contrasts key principle)
7. Viral oncoproteins (HPV E7, SV40 T) target both p53 and RB, demonstrating their importance
8. Understanding these pathways guides both cancer prevention (surveillance in hereditary syndromes) and treatment (CDK inhibitors, MDM2 inhibitors, immunotherapy)

---

## REFERENCES

- Robbins & Kumar Basic Pathology (9th Edition): Chapter 6 - Genetic Basis of Cancer
- Harper's Illustrated Biochemistry (32nd Edition): Section XI - DNA & Cell Cycle
- Basic Medical Biochemistry: Chapter 17 - p53, The Guardian of the Genome
- Campbell Walsh Wein Urology: Molecular Basis of Cancer
- Berek & Novak's Gynecology: Cell Division Cycle Genes
- Dermatology 2-Volume Set: Mutations in p53 and Rb Tumor Suppressor Pathways
- Harrison's Principles of Internal Medicine (22E): Molecular Classification and Tumor Suppressor Gene Inactivation

---

**Total Marks Distribution:**
- Introduction: 1 mark
- General characteristics (two-hit, mechanisms, categories): 2 marks
- RB structure, function, cell cycle control, clinical significance: 3.5 marks
- p53 structure, function, DNA damage response, apoptosis: 3.5 marks
- Comparative analysis & integration: 1 mark
- Clinical relevance: 1 mark
- **Total: 10 marks**